PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35545360-13 2022 CONCLUSIONS: APS can regulate the miR-16/NF-kappaB signaling pathway, thereby affecting the levels of MDR1 and P-gp170, and reducing the inflammation in the kidney tissues in the adriamycin nephropathy rats. Doxorubicin 179-189 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 102-106 29176019-7 2017 CONCLUSIONS: The findings indicate that the A. cominia extract modulates the CYP and P-gp systems increasing sensitivity to doxorubicin. Doxorubicin 124-135 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 85-89 32106718-0 2022 Montelukast ameliorates doxorubicin-induced cardiotoxicity via modulation of p-glycoprotein and inhibition of ROS-mediated TNF-alpha/NF-kappaB pathways. Doxorubicin 24-35 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 77-91 25581352-8 2015 In Caco-2 uptake studies, PLV2K-DOX micelles significantly improve the internalized amount of DOX by P-gp inhibition of free PLV2K copolymer and endocytosis of DOX-loaded nanoparticles. Doxorubicin 32-35 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 101-105 26530267-0 2016 Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. Doxorubicin 22-33 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 59-73 26530267-10 2016 Collectively, our findings suggest that temozolomide can reverse doxorubicin resistance by directly affecting P-gp transport activity. Doxorubicin 65-76 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 110-114 25581352-8 2015 In Caco-2 uptake studies, PLV2K-DOX micelles significantly improve the internalized amount of DOX by P-gp inhibition of free PLV2K copolymer and endocytosis of DOX-loaded nanoparticles. Doxorubicin 94-97 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 101-105 25581352-8 2015 In Caco-2 uptake studies, PLV2K-DOX micelles significantly improve the internalized amount of DOX by P-gp inhibition of free PLV2K copolymer and endocytosis of DOX-loaded nanoparticles. Doxorubicin 94-97 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 101-105 22161812-8 2013 The cell survival of RHa3G8 cells treated with cisplatin (CDDP) or doxorubicin (DOX) was higher than that of RH7777AB cells, correlating with the elevated expression levels of multidrug-resistance related genes, Mdr1a, Mdr1b, and Gstp1. Doxorubicin 67-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 219-224 24632013-0 2014 Protective mechanisms of coenzyme-Q10 may involve up-regulation of testicular P-glycoprotein in doxorubicin-induced toxicity. Doxorubicin 96-107 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 78-92 24632013-2 2014 P-glycoprotein (P-gp) is a multidrug resistance efflux transporter expressed in blood-testis barrier, which extrudes DOX from the testis. Doxorubicin 117-120 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 24632013-2 2014 P-glycoprotein (P-gp) is a multidrug resistance efflux transporter expressed in blood-testis barrier, which extrudes DOX from the testis. Doxorubicin 117-120 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 16-20 24632013-7 2014 Concomitant administration of CoQ10 with DOX significantly restored testicular oxidative stress parameters and the distorted histopathological picture, reduced the up-regulation of caspase 3 caused by DOX, and increased P-gp expression. Doxorubicin 41-44 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 220-224 24632013-9 2014 In conclusion, CoQ10 protects against DOX-induced testicular toxicity in rats via ameliorating oxidative stress, reducing apoptosis and up-regulating testicular P-gp. Doxorubicin 38-41 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 161-165 23770382-12 2013 Consistent with in vitro profile, oral dose of 40mg/kg nilotinib significantly decreased the cardiotoxicity of DOX in rat by enhancing P-gp activity in the heart. Doxorubicin 111-114 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 135-139 23574017-3 2013 Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 49-63 23574017-3 2013 Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 65-69 23878263-6 2013 Functionally, LSS-activated PXR protects ECs from apoptosis triggered by doxorubicin via the induction of MDR1 and other detoxification genes. Doxorubicin 73-84 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 106-110 23630447-12 2013 In vitro studies confirmed that inhibition of MDR1 by verapamil in rat H9C2 cardiomyocytes increased their susceptibility to doxorubicin-induced toxicity. Doxorubicin 125-136 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 46-50 22161812-8 2013 The cell survival of RHa3G8 cells treated with cisplatin (CDDP) or doxorubicin (DOX) was higher than that of RH7777AB cells, correlating with the elevated expression levels of multidrug-resistance related genes, Mdr1a, Mdr1b, and Gstp1. Doxorubicin 80-83 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 219-224 17090397-5 2006 In the case of free Dox in solution, this difference correlated with different intracellular concentrations of Dox, which in turn, depended on the level of P-glycoprotein (P-gp) expression in these cell lines. Doxorubicin 20-23 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 156-170 21822614-0 2011 A probable relationship between characteristic accumulation of doxorubicin and P-glycoprotein transporter in rat liver. Doxorubicin 63-74 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 79-93 22361031-0 2012 Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. Doxorubicin 116-127 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 17-31 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Doxorubicin 115-126 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 21-35 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Doxorubicin 115-126 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Doxorubicin 128-131 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 21-35 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Doxorubicin 128-131 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Doxorubicin 171-174 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 21-35 22361031-1 2012 Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. Doxorubicin 171-174 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 22361031-2 2012 The purpose of this study was to evaluate whether the effect of these P-gp inhibitors on the pharmacokinetics of DOX can be avoided through their encapsulation in polymeric micelles. Doxorubicin 113-116 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 70-74 21737631-2 2011 The aim of this study was to assess whether tumor uptake of doxorubicin, administered locoregionally by ILP, would be increased by the administration of P-glycoprotein (P-gp) modulators. Doxorubicin 60-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 153-167 21737631-2 2011 The aim of this study was to assess whether tumor uptake of doxorubicin, administered locoregionally by ILP, would be increased by the administration of P-glycoprotein (P-gp) modulators. Doxorubicin 60-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 169-173 21699081-2 2011 These Citrus flavonoids are known as P-glycoprotein (P-gp) inhibitors and thus suspected to interact with doxorubicin, as shown by in vitro cell studies. Doxorubicin 106-117 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-51 21699081-2 2011 These Citrus flavonoids are known as P-glycoprotein (P-gp) inhibitors and thus suspected to interact with doxorubicin, as shown by in vitro cell studies. Doxorubicin 106-117 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 53-57 21544726-12 2011 These results suggest that the quercetin-induced increase in bioavailability of oral doxorubicin can be attributed to enhanced doxorubicin absorption in the gastrointestinal tract via quercetin-induced inhibition of P-gp and reduced first-pass metabolism of doxorubicin due to quercetin-induced inhibition of CYP3A in the small intestine and/or in the liver rather than reduced renal and/or hepatic elimination of doxorubicin. Doxorubicin 85-96 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 216-220 21380815-11 2011 These results suggest that the increase in the oral bioavailability of DOX might be mainly attributed to enhanced absorption in the gastrointestinal tract via the inhibition of P-gp and to reduced first-pass metabolism of DOX due to inhibition of CYP3A in the small intestine and/or in the liver by myricetin. Doxorubicin 71-74 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 177-181 19827298-10 2009 The enhanced bioavailability of oral DOX by oral baicalein may be due to the inhibition of both P-glycoprotein (P-gp) and the cytochrome P450 (CYP) 3A subfamily by baicalein in the intestine and/or liver. Doxorubicin 37-40 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 96-110 19827298-10 2009 The enhanced bioavailability of oral DOX by oral baicalein may be due to the inhibition of both P-glycoprotein (P-gp) and the cytochrome P450 (CYP) 3A subfamily by baicalein in the intestine and/or liver. Doxorubicin 37-40 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 112-116 17090397-5 2006 In the case of free Dox in solution, this difference correlated with different intracellular concentrations of Dox, which in turn, depended on the level of P-glycoprotein (P-gp) expression in these cell lines. Doxorubicin 20-23 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 172-176 17090397-5 2006 In the case of free Dox in solution, this difference correlated with different intracellular concentrations of Dox, which in turn, depended on the level of P-glycoprotein (P-gp) expression in these cell lines. Doxorubicin 111-114 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 156-170 17090397-5 2006 In the case of free Dox in solution, this difference correlated with different intracellular concentrations of Dox, which in turn, depended on the level of P-glycoprotein (P-gp) expression in these cell lines. Doxorubicin 111-114 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 172-176 16377671-7 2006 When the effect of telithromycin on the biliary excretion of doxorubicin, a substrate of P glycoprotein and Mrp2, was examined in SD rats, telithromycin significantly decreased the biliary clearance of doxorubicin by 80%. Doxorubicin 61-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-103 16483613-4 2006 However, the net biliary clearance of doxorubicin based on the liver concentration, which represents the actual function of P-glycoprotein and/or Mrp2, was higher in female rats than in male rats. Doxorubicin 38-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 124-138 16353156-6 2006 Cyclosporin A, a competitive inhibitor of Pgp, increased the intracellular accumulation of DOX and reduced the resistance to it. Doxorubicin 91-94 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 42-45 16540558-0 2006 Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). Doxorubicin 71-81 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 102-132 16540558-0 2006 Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). Doxorubicin 71-81 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 134-148 16540558-3 2006 It was shown previously that adenovirus-mediated gene transfer of COX-2 into rat GMC led to increased expression and activity of multidrug resistance protein 1 (MDR-1), a membrane transporter that functions as an efflux pump for chemotherapeutic drugs, including Adriamycin (ADR). Doxorubicin 263-273 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 129-159 16540558-3 2006 It was shown previously that adenovirus-mediated gene transfer of COX-2 into rat GMC led to increased expression and activity of multidrug resistance protein 1 (MDR-1), a membrane transporter that functions as an efflux pump for chemotherapeutic drugs, including Adriamycin (ADR). Doxorubicin 263-273 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 161-166 14622113-0 2003 P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes. Doxorubicin 95-106 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 15937726-0 2005 Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin. Doxorubicin 151-162 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 48-62 15937726-2 2005 We investigated the influence of a Pgp modulator (tamoxifen, TAM) on the pharmacokinetics and toxicodynamics of a Pgp substrate (doxorubicin, DOX) in rats. Doxorubicin 129-140 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 35-38 15937726-2 2005 We investigated the influence of a Pgp modulator (tamoxifen, TAM) on the pharmacokinetics and toxicodynamics of a Pgp substrate (doxorubicin, DOX) in rats. Doxorubicin 129-140 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 114-117 15937726-2 2005 We investigated the influence of a Pgp modulator (tamoxifen, TAM) on the pharmacokinetics and toxicodynamics of a Pgp substrate (doxorubicin, DOX) in rats. Doxorubicin 142-145 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 114-117 15937726-13 2005 The activity declined and reached a plateau at 20% of the basal activity after 6 h and remained at that level for 24 h. The area under the curves of Pgp-ATPase activity time (AUC(Activity 0-24)) following DOX administration in TAM-treated group was significantly lower than that of the control group, indicating an overall inhibitory effect of TAM on Pgp-ATPase activity under the protocol of this study. Doxorubicin 205-208 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 149-152 15937726-13 2005 The activity declined and reached a plateau at 20% of the basal activity after 6 h and remained at that level for 24 h. The area under the curves of Pgp-ATPase activity time (AUC(Activity 0-24)) following DOX administration in TAM-treated group was significantly lower than that of the control group, indicating an overall inhibitory effect of TAM on Pgp-ATPase activity under the protocol of this study. Doxorubicin 205-208 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 351-354 15937726-15 2005 The amount of myocardial Pgp in the 24-h period following DOX administration was comparable to the control group and showed no significant deviation from the basal levels of the protein. Doxorubicin 58-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 25-28 15937726-16 2005 CONCLUSIONS: The effect of TAM on DOX accumulation in the myocardial tissue and the increase in cardiotoxicity can be related to the net inhibitory effect of TAM on the efflux activity of Pgp in the heart. Doxorubicin 34-37 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 188-191 15937726-17 2005 The results of the present study supported the hypothesis of the project that multiple regimen pretreatment with Pgp modulator TAM increases the DOX accumulation in the heart and promotes DOX-induced cardiotoxicity. Doxorubicin 145-148 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 113-116 15937726-17 2005 The results of the present study supported the hypothesis of the project that multiple regimen pretreatment with Pgp modulator TAM increases the DOX accumulation in the heart and promotes DOX-induced cardiotoxicity. Doxorubicin 188-191 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 113-116 14744620-1 2004 The present study aims to investigate whether azithromycin reverses P-glycoprotein-dependent anticancer drug resistance in vitro and modifies the hepatobiliary excretion of doxorubicin, a substrate for P-glycoprotein in vivo. Doxorubicin 173-184 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 202-216 16126379-3 2006 We hypothesized that stealth liposomal co-encapsulation of doxorubicin (DOX) with a P-glycoprotein inhibitor, verapamil (DARSLs), may overcome these limitations. Doxorubicin 59-70 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 84-98 14622113-2 2003 The aim of this study was to compare the expression of P-gp and Mrp1 in primary cultures exposed to 50 or 500 ng/mL doxorubicin (DOX). Doxorubicin 116-127 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 55-59 14622113-2 2003 The aim of this study was to compare the expression of P-gp and Mrp1 in primary cultures exposed to 50 or 500 ng/mL doxorubicin (DOX). Doxorubicin 129-132 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 55-59 14622113-5 2003 In addition, DOX also strongly enhanced, in a time- and dose-dependent manner, P-gp but not Mrp1 expression. Doxorubicin 13-16 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 79-83 14622113-6 2003 Moreover, DOX raised the cellular efflux of vincristine, a substrate for both P-gp and Mrp1. Doxorubicin 10-13 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 78-82 14622113-11 2003 Our results provide evidence that DOX up-regulates a functional P-gp in primary cultures of rat astrocytes and might cause astrocyte apoptosis via the ceramide pathway. Doxorubicin 34-37 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 64-68 12709333-0 2003 Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Doxorubicin 55-66 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 105-119 12709333-1 2003 We investigated the effect of Shiga-like toxin II (SLT-II), derived from Escherichia coli O157:H7, on the hepatobiliary excretion of doxorubicin, a substrate for P glycoprotein and the multidrug resistance-associated protein Mrp2, and on the expression of P glycoprotein and Mrp2 in rats. Doxorubicin 133-144 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 162-176 12709333-1 2003 We investigated the effect of Shiga-like toxin II (SLT-II), derived from Escherichia coli O157:H7, on the hepatobiliary excretion of doxorubicin, a substrate for P glycoprotein and the multidrug resistance-associated protein Mrp2, and on the expression of P glycoprotein and Mrp2 in rats. Doxorubicin 133-144 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 256-270 12709333-7 2003 Western blot analysis revealed that SLT-II down-regulated P glycoprotein and Mrp2 in the liver, which could explain the observed decrease in the biliary excretion of doxorubicin by SLT-II. Doxorubicin 166-177 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 58-72 11062690-0 2000 Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Doxorubicin 82-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-51 11062690-5 2000 These results suggest that erythromycin competitively inhibits P-glycoprotein-mediated biliary and renal excretion of doxorubicin. Doxorubicin 118-129 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 63-77 12113888-3 2002 Doxorubicin was used as a P-gp substrate. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 26-30 11724350-1 2001 In tumor cells, doxorubicin (DOX) is excreted by P-glycoprotein (P-gp) and the multidrug resistance-associated protein (mrp). Doxorubicin 16-27 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 49-63 11724350-1 2001 In tumor cells, doxorubicin (DOX) is excreted by P-glycoprotein (P-gp) and the multidrug resistance-associated protein (mrp). Doxorubicin 16-27 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 65-69 11724350-1 2001 In tumor cells, doxorubicin (DOX) is excreted by P-glycoprotein (P-gp) and the multidrug resistance-associated protein (mrp). Doxorubicin 29-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 49-63 11724350-1 2001 In tumor cells, doxorubicin (DOX) is excreted by P-glycoprotein (P-gp) and the multidrug resistance-associated protein (mrp). Doxorubicin 29-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 65-69 11724350-9 2001 Our data show that in the liver of both strains, exposure to a hypotonic medium stimulates DOX excretion, presumably by activation of P-gp and mrp2 during RVD. Doxorubicin 91-94 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 134-138 11062690-8 2000 The findings of these experiments suggest that the inhibitory effect of erythromycin on the P-glycoprotein-mediated biliary excretion of doxorubicin is competitive and that combination chemotherapy of doxorubicin with erythromycin may induce toxicity as a result of increased plasma concentrations of doxorubicin. Doxorubicin 137-148 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 92-106 11062690-8 2000 The findings of these experiments suggest that the inhibitory effect of erythromycin on the P-glycoprotein-mediated biliary excretion of doxorubicin is competitive and that combination chemotherapy of doxorubicin with erythromycin may induce toxicity as a result of increased plasma concentrations of doxorubicin. Doxorubicin 201-212 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 92-106 11062690-8 2000 The findings of these experiments suggest that the inhibitory effect of erythromycin on the P-glycoprotein-mediated biliary excretion of doxorubicin is competitive and that combination chemotherapy of doxorubicin with erythromycin may induce toxicity as a result of increased plasma concentrations of doxorubicin. Doxorubicin 201-212 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 92-106 9780140-1 1998 Several lipophilic, cytotoxic drugs, or both, (including anticancer drugs [Vinca alkaloids, doxorubicin, cyclosporin A, and digoxin]) have proven to be actively effluxed by P-glycoprotein (P-gp) expressed at the luminal membrane of the brain capillary endothelial cells, resulting in the very low apparent blood-brain barrier (BBB) permeation of these P-gp substrates from the blood circulating to the brain. Doxorubicin 92-103 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 173-187 10494879-8 1999 Okadaic acid resistance included cross-resistance to other cytotoxic agents that are substrates of mdr1-type P-glycoproteins, like doxorubicin and actinomycin D, but not to non-substrates of mdr1, e.g. cytosine arabinoside. Doxorubicin 131-142 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-103 10368660-3 1999 The reverting agent verapamil, that is a substrate for P-glycoprotein, inhibited doxorubicin uptake in intact mast cells in a dose and time dependent manner, but had no effect on the exocytotic action of the antineoplastic drug. Doxorubicin 81-92 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 55-69 10368660-5 1999 Verapamil and vinblastine, another substrate for P-glycoprotein, significantly reduced doxorubicin concentrations in intact granules. Doxorubicin 87-98 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 49-63 10368660-10 1999 These data suggest the presence of a P-glycoprotein active in the transport of doxorubicin, in mast cell granules. Doxorubicin 79-90 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-51 10190554-3 1999 Several factors shown to induce mdr1 overexpression (UV irradiation, epidermal growth factor, tumour necrosis factor alpha, doxorubicin) have been associated with the generation of reactive oxygen species (ROS). Doxorubicin 124-135 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 32-36 9504375-20 1998 Our data are compatible with a potential involvement of P-glycoprotein in the hepatobiliary excretion of doxorubicin as well as of some type 1 and type 2 organic cations. Doxorubicin 105-116 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 56-70 9525837-0 1998 Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. Doxorubicin 14-25 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 108-122 9525837-4 1998 It follows that inhibition of Pgp would alter the pharmacokinetics of drugs, like doxorubicin, in cells that express Pgp. Doxorubicin 82-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 30-33 9525837-4 1998 It follows that inhibition of Pgp would alter the pharmacokinetics of drugs, like doxorubicin, in cells that express Pgp. Doxorubicin 82-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 117-120 9525837-9 1998 Unlike CDDP, Dox, can be effluxed by Pgp. Doxorubicin 13-16 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-40 9721873-3 1998 Quinidine and GF120918 inhibit the transport of P-gp substrates, including doxorubicin. Doxorubicin 75-86 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 48-52 9210482-0 1997 Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Doxorubicin 71-82 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 17-31 9395229-5 1997 In long-term colony survival assays, stably expressed mdr1b conferred resistance to cytotoxic drugs such as colchicine, vinblastine and doxorubicin, but not to 5-fluorouracil nor to the carcinogens aflatoxin B1 and N-hydroxy-acetylaminofluorene. Doxorubicin 136-147 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 54-59 9210482-1 1997 Expression of P-glycoprotein, a plasma-membrane glycoprotein involved in multidrug resistance and encoded by mdr genes, was investigated in cultured rat liver cells acutely exposed to doxorubicin. Doxorubicin 184-195 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 9210482-5 1997 In addition, RLE cells exposed to doxorubicin displayed an overexpression of a 140-kDa P-glycoprotein as demonstrated by western blotting. Doxorubicin 34-45 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 87-101 9210482-6 1997 Moreover, doxorubicin-treated RLE cells displayed enhanced cellular efflux of the P-glycoprotein substrate rhodamine 123 that was inhibited by the P-glycoprotein blocker verapamil, thus providing evidence that doxorubicin-induced P-glycoprotein was functional in liver cells. Doxorubicin 10-21 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 82-96 9210482-6 1997 Moreover, doxorubicin-treated RLE cells displayed enhanced cellular efflux of the P-glycoprotein substrate rhodamine 123 that was inhibited by the P-glycoprotein blocker verapamil, thus providing evidence that doxorubicin-induced P-glycoprotein was functional in liver cells. Doxorubicin 10-21 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 147-161 9210482-6 1997 Moreover, doxorubicin-treated RLE cells displayed enhanced cellular efflux of the P-glycoprotein substrate rhodamine 123 that was inhibited by the P-glycoprotein blocker verapamil, thus providing evidence that doxorubicin-induced P-glycoprotein was functional in liver cells. Doxorubicin 10-21 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 147-161 9210482-6 1997 Moreover, doxorubicin-treated RLE cells displayed enhanced cellular efflux of the P-glycoprotein substrate rhodamine 123 that was inhibited by the P-glycoprotein blocker verapamil, thus providing evidence that doxorubicin-induced P-glycoprotein was functional in liver cells. Doxorubicin 210-221 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 82-96 9210482-6 1997 Moreover, doxorubicin-treated RLE cells displayed enhanced cellular efflux of the P-glycoprotein substrate rhodamine 123 that was inhibited by the P-glycoprotein blocker verapamil, thus providing evidence that doxorubicin-induced P-glycoprotein was functional in liver cells. Doxorubicin 210-221 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 147-161 9210482-6 1997 Moreover, doxorubicin-treated RLE cells displayed enhanced cellular efflux of the P-glycoprotein substrate rhodamine 123 that was inhibited by the P-glycoprotein blocker verapamil, thus providing evidence that doxorubicin-induced P-glycoprotein was functional in liver cells. Doxorubicin 210-221 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 147-161 9210482-9 1997 These data indicate that doxorubicin can act as a potent acute inducer of functional P-glycoprotein in rat liver cells and therefore may modulate both chemosensitivity of hepatic cells and P-glycoprotein-mediated biliary secretion of xenobiotics. Doxorubicin 25-36 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 85-99 9210482-9 1997 These data indicate that doxorubicin can act as a potent acute inducer of functional P-glycoprotein in rat liver cells and therefore may modulate both chemosensitivity of hepatic cells and P-glycoprotein-mediated biliary secretion of xenobiotics. Doxorubicin 25-36 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 189-203 7763297-0 1995 In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Doxorubicin 86-97 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 52-66 8640928-3 1996 Rat hepatocytes exposed to 2-AAF were also found to accumulate doxorubicin, an anticancer drug known to be transported by P-gp, poorly, thereby demonstrating that 2-AAF-mediated mdr1 induction resulted in increased P-gp activity. Doxorubicin 63-74 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 122-126 8640928-3 1996 Rat hepatocytes exposed to 2-AAF were also found to accumulate doxorubicin, an anticancer drug known to be transported by P-gp, poorly, thereby demonstrating that 2-AAF-mediated mdr1 induction resulted in increased P-gp activity. Doxorubicin 63-74 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 178-182 7763297-4 1995 The uptake of DOX by primary cultured brain capillary endothelial cells expressing P-gp at the luminal membrane was increased significantly (up to 2-fold), which correlated well with the decrease of cellular ATP contents caused by treating the cells with metabolic inhibitors. Doxorubicin 14-17 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 83-87 7763297-1 1995 We investigated the role of ATP in the active efflux of doxorubicin (DOX) mediated by P-glycoprotein (P-gp), the multidrug-resistance (MDR) gene product, at the blood-brain barrier. Doxorubicin 56-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 86-100 7763297-5 1995 Evidence for the ATP-dependent transport of DOX obtained from the present in vivo and in vitro studies strongly indicates that P-gp in the brain capillaries functions actively as an efflux pump in the physiological state, providing a major mechanism to restrict the transfer of DOX into the brain. Doxorubicin 44-47 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 127-131 7763297-5 1995 Evidence for the ATP-dependent transport of DOX obtained from the present in vivo and in vitro studies strongly indicates that P-gp in the brain capillaries functions actively as an efflux pump in the physiological state, providing a major mechanism to restrict the transfer of DOX into the brain. Doxorubicin 278-281 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 127-131 7763297-1 1995 We investigated the role of ATP in the active efflux of doxorubicin (DOX) mediated by P-glycoprotein (P-gp), the multidrug-resistance (MDR) gene product, at the blood-brain barrier. Doxorubicin 56-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 102-106 7763297-1 1995 We investigated the role of ATP in the active efflux of doxorubicin (DOX) mediated by P-glycoprotein (P-gp), the multidrug-resistance (MDR) gene product, at the blood-brain barrier. Doxorubicin 69-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 86-100 7763297-1 1995 We investigated the role of ATP in the active efflux of doxorubicin (DOX) mediated by P-glycoprotein (P-gp), the multidrug-resistance (MDR) gene product, at the blood-brain barrier. Doxorubicin 69-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 102-106 7475916-3 1995 In 72h-cultured hepatocytes, spontaneously overexpressing functional Pgp, flavonols inhibited R-123 efflux in a dose-dependent manner, but significantly reduced DOX retention while increasing its efflux. Doxorubicin 161-164 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 69-72 8101494-5 1993 Doxorubicin P-gp-mediated efflux analyses revealed lower intracellular doxorubicin accumulation in DEX-untreated liver cells than in DEX-treated cells, thus indicating that over-expressed P-gp was functional. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 12-16 7913321-8 1994 This P-glycoprotein was functional and this overexpression was correlated with a decrease of doxorubicin retention in hepatocytes. Doxorubicin 93-104 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 5-19 8101494-5 1993 Doxorubicin P-gp-mediated efflux analyses revealed lower intracellular doxorubicin accumulation in DEX-untreated liver cells than in DEX-treated cells, thus indicating that over-expressed P-gp was functional. Doxorubicin 71-82 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 12-16 7910810-6 1994 Doxorubicin challenge of the initially drug-sensitive parental prostatic carcinoma cell lines resulted in the rapid development of multidrug resistance together with simultaneous expression of P-glycoprotein. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 193-207 7910810-8 1994 This study has shown that Dunning rat prostate-carcinoma cell lines, previously sensitive to different cytotoxic agents, rapidly become multidrug-resistant and express P-glycoprotein following exposure to doxorubicin. Doxorubicin 205-216 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 168-182 21566973-0 1994 Doxorubicin enhances transient expression of p-glycoprotein and modulates activity and isoform expression of protein-kinase-C in ah66 rat hepatoma-cells. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 45-59 7905826-7 1994 These cells were strongly resistant to doxorubicin and vinblastine, two anticancer drugs transported by P-glycoprotein. Doxorubicin 39-50 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 104-118 7905826-8 1994 Doxorubicin intracellular retention was low in RHC1 and RHC2 cells, but was strongly enhanced in the presence of verapamil, a known modulator agent of P-glycoprotein; low retention appeared to occur via a drug efflux mechanism, indicating that P-glycoprotein was fully active. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 151-165 7905826-8 1994 Doxorubicin intracellular retention was low in RHC1 and RHC2 cells, but was strongly enhanced in the presence of verapamil, a known modulator agent of P-glycoprotein; low retention appeared to occur via a drug efflux mechanism, indicating that P-glycoprotein was fully active. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 244-258 8402643-1 1993 Verapamil reverses multidrug resistance acquired by cancer cells during treatment with chemotherapeutic agents such as doxorubicin by inhibiting the function of P-glycoprotein. Doxorubicin 119-130 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 161-175 8102127-0 1993 Differential over-expression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine. Doxorubicin 108-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 32-36 8101494-5 1993 Doxorubicin P-gp-mediated efflux analyses revealed lower intracellular doxorubicin accumulation in DEX-untreated liver cells than in DEX-treated cells, thus indicating that over-expressed P-gp was functional. Doxorubicin 0-11 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 188-192 8101494-5 1993 Doxorubicin P-gp-mediated efflux analyses revealed lower intracellular doxorubicin accumulation in DEX-untreated liver cells than in DEX-treated cells, thus indicating that over-expressed P-gp was functional. Doxorubicin 71-82 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 188-192 8104817-11 1993 Accordingly, it is suggested that hydrophobic drugs such as doxorubicin, being pumped out by P-glycoprotein, do not accumulate in 9L glioma cells as do other lipophilic drugs such as ACNU, or drugs such as 5-FU, which accumulate by a carrier-mediated mechanism. Doxorubicin 60-71 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 93-107 1982215-1 1990 The MDR1 gene encodes an Mr 170,000 energy-dependent drug efflux pump (P-glycoprotein) which transports hydrophobic agents such as Adriamycin, colchicine, the Vinca alkaloids, and actinomycin D out of cells. Doxorubicin 131-141 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 4-8 1349283-4 1992 This increased expression of P-gp was associated with decreased intracellular retention of doxorubicin, which could be restored by compounds such as verapamil and cyclosporin; doxorubicin (and also vincristine) was more cytotoxic to early than to late cultures. Doxorubicin 91-102 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 29-33 1349283-4 1992 This increased expression of P-gp was associated with decreased intracellular retention of doxorubicin, which could be restored by compounds such as verapamil and cyclosporin; doxorubicin (and also vincristine) was more cytotoxic to early than to late cultures. Doxorubicin 176-187 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 29-33 1361732-3 1992 P-gp overexpression, estimated by northern blotting and doxorubicin-mediated drug efflux analyses, was similarly observed during culture in both standard and proliferating conditions, while it was delayed, but not inhibited, in the presence of DMSO or nicotinamide. Doxorubicin 56-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 1348623-1 1992 We have associated pharmacological studies to a semi-quantitative evaluation of P-glycoprotein(s) expression, to establish if classical multidrug resistance (MDR) could account for the complete resistance phenotype exhibited by progressively doxorubicin-resistant rat glioblastoma cells. Doxorubicin 242-253 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 80-94 27720963-5 2017 After oral administration of DOX:NGs/Qu-M-ALG-Beads in rats, DOX was effectively delivered into systemic circulation due to P-gp inhibitory properties of Qu. Doxorubicin 29-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 124-128 27720963-5 2017 After oral administration of DOX:NGs/Qu-M-ALG-Beads in rats, DOX was effectively delivered into systemic circulation due to P-gp inhibitory properties of Qu. Doxorubicin 61-64 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 124-128